LAVAL, Que. – Valeant Pharmaceuticals International, Inc. (TSX:VRX) has a friendly deal to acquire Solta Medical, Inc. a California-based company that makes medical devices used in cosmetic surgery procedures.
Get breaking National news
For news impacting Canada and around the world, sign up for breaking news alerts delivered directly to you when they happen.
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy.
The Montreal-area company’s offer of US$2.92 per share for all of Solta’s stock is valued at US$250 million, a 40 per cent premium to Friday’s closing price on Nasdaq.
Solta’s board of directors supports offer, which requires that Valeant gets at least a majority of Solta’s shares.
Comments